FIRST REPORT OF THE PHASE-I STUDY OF THE NOVEL ORAL JAK2 INHIBITOR SB1518 IN PATIENTS WITH MYELOFIBROSIS

被引：0

作者：

Seymour, F. ^{[1
]}

To, B. ^{[2
]}

Goh, A. ^{[3
]}

Meadows, L. ^{[1
]}

Ethirajulu, A. ^{[3
]}

Wood, A. ^{[3
]}

Zhu, A. ^{[4
]}

Roberts, W. ^{[5
]}

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Australia

[2] Royal Adelaide Hosp, Inst Med & Vet Sci, Adelaide, SA 5000, Australia

[3] S BIO Pty Ltd, Singapore, Singapore

[4] S BIO Pty Ltd, Redwood City, CA USA

[5] Royal Melbourne Hosp, Parkville, Vic 3050, Australia

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1144

引用

页码：472 / 472

页数：1

共 50 条

[1] Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis
Deeg, H. J.
Odenike, O.
Scott, B. L.
Estrov, Z.
Cortes, J. E.
Thomas, D. A.
Zhu, H. J.
Kantarjian, H.
Verstovsek, S.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[2] Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
Komrokji, Rami S.
Seymour, John F.
Roberts, Andrew W.
Wadleigh, Martha
To, L. Bik
Scherber, Robyn
Turba, Elyce
Dorr, Andrew
Zhu, Joy
Wang, Lixia
Granston, Tanya
Campbell, Mary S.
Mesa, Ruben A.
BLOOD, 2015, 125 (17) : 2649 - 2655
[3] Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity
Younes, Anas
Fanale, Michelle
McLaughlin, Peter
Copeland, Amanda R.
Faria, Silvana de Castro
Wood, Jeanette
Ethirajulu, Kantharaj
Zhu, Huan J.
BLOOD, 2009, 114 (22) : 244 - 244
[4] Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis
Verstovsek, Srdan
Deeg, H. Joachim
Odenike, Olatoyosi
Zhu, Joy
Kantarjian, Hagop
Estrov, Zeev
Scott, Bart Lee
Thomas, Deborah A.
BLOOD, 2010, 116 (21) : 1271 - 1271
[5] Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis
Komrokji, Rami S.
Wadleigh, Martha
Seymour, John F.
Roberts, Andrew W.
To, Luen Bik
Zhu, Huan J.
Mesa, Ruben A.
BLOOD, 2011, 118 (21) : 130 - 131
[6] CHARACTERIZATION OF THE PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF PACRITINIB (SB1518), A NOVEL ORAL JAK2/FLT3 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS, AML AND LYMPHOMA
Al-Fayoumi, S.
Wang, L.
Dean, J.
Benner, S.
HAEMATOLOGICA, 2013, 98 : 406 - 406
[7] PHASE 1 STUDY OF A NOVEL ORAL JAK2 INHIBITOR, SB1518, IN PATIENTS WITH RELAPSED LYMPHOMA: EVIDENCE OF CLINICAL AND BIOLOGIC ACTIVITY IN MULTIPLE LYMPHOMA SUBTYPES
Younes, A.
Fanale, M.
Mclaughlin, P.
Copeland, A.
Faria, S. De Castro
Zhu, J.
ANNALS OF ONCOLOGY, 2011, 22 : 136 - 137
[8] SB1518, a novel JAK2/FLT3 inhibitor for the treatment of myeloid malignancies
Hart, Stefan
Goh, Kee Chuan
Novotny-Diermayr, Veronica Veronica
Tan, Yong Cheng
Madan, Babita
Amalini, Chithra
Loh, Yung Kiang
Ong, Lai Chun
Williams, Anthony
Lee, Angeline
Poulsen, Anders
Jayaraman, Ramesh
Ethirajulu, Kantharaj
Dymock, Brian W.
Wood, Jeanette M.
CANCER RESEARCH, 2011, 71
[9] Phase I Study of a Novel Oral JAK-2 Inhibitor SB1518 In Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes
Younes, Anas
Fanale, Michelle A.
McLaughlin, Peter
Copeland, Amanda
Zhu, Joy
Faria, Silvania de Castro
BLOOD, 2010, 116 (21) : 1167 - 1167
[10] Design, synthesis and SAR studies leading to SB1518, a novel macrocyclic JAK2/FLT3 inhibitor in phase 2 clinical trials for myelofibrosis and lymphoma
Lee, Angeline
William, Anthony
Poulsen, Anders
Tan, Evelyn
Nagaraj, Harish
Goh, Kay Lin
Ong, Wai Chung
Goh, Kee Chuan
Pasha, Mohammed Khalid
Jayaraman, Ramesh
Ethirajulu, Kantharaj
Wood, Jeanette M.
Dymock, Brian W.
CANCER RESEARCH, 2011, 71

← 1 2 3 4 5 →